Acute Myeloid Leukemia (AML)
Conditions
Keywords
Venclyxto, Venetoclax, Azacitidine, Hematologic Diseases, Acute Myelogenous Leukemia
Brief summary
Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for intensive induction therapy ineligible AML patients in Germany The VENAZA-5S pilot trial: AZA administration reduced to 5 days within each cycle to improve tolerability and treatment adherence due to less neutropenic infections, less treatment interruptions and less hospitalizations.
Detailed description
Acute myeloid leukemia (AML) is a uniformly fatal disease if untreated. The combination of continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle has recently emerged as the new standard of care for AML patient who are ineligible for intensive induction therapy, and has been widely adopted in Germany. The VENAZA-5S pilot trial aims to reduce the reported hematological toxicity profile of this currently approved combination, while preserving efficacy, by modifying AZA administration to 5 days within each cycle. The hypothesis is that this modification will not interfere with the response rates achieved by the combination, but will rather improve tolerability and treatment adherence due to less neutropenic infections, less treatment interruptions and hospitalizations, and thus result in better quality of life and favorable long-term outcomes in elderly or comorbid AML patients. This single-arm pilot study is intended to generate first data on the efficacy and toxicity of 5 days AZA + VEN, which will be compared to a historical control cohort treated with the current standard of 7 days AZA + VEN.
Interventions
DRUGVEN+AZA-5
Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Sponsors
University of Leipzig
AbbVie
University Hospital Leipzig, Hematology Diagnostics Laboratory
University of Leipzig, Clinical Trial Centre (ZKS)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Confirmed diagnosis of AML by World Health Organization (WHO) criteria 2016 * Ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities * Age ≥ 18 years * Life expectancy of at least 12 weeks Key
Exclusion criteria
* Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following: * Hypomethylating agent (HMA) * Chemotherapeutic agent * Chimeric Antigen Receptor (CAR)-T cell therapy * Experimental therapies * Note: Prior use of hydroxyurea is allowed * History of myeloproliferative neoplasm (MPN) * Diagnosis of acute promyelocytic leukemia (APL) * Presence of favorable-risk karyotype abnormalities: t(15;17), t(8;21), inv(16) or t(16;16)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome measure is the response rate defined as the rate of CR/CRi after up to 6 cycles of therapy (best response). | best response after up to 6 cycles (each cycle is 28 days) | Bone marrow assessments will be performed at least at screening, at the end of cycle 1, after cycle 4 and after cycle 6 resp. end of treatment (EOT). Criteria for disease status / response assessment follow the ELN-2022 recommendations . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of CR or CRi by the Initiation of Cycle 2 | At the end of Cycle 1 (each cycle is 28 days) | Rate of CR or CRi by the Initiation of Cycle 2. Criteria for disease status / response assessment follow the European LeukemiaNet (ELN) - 2022 recommendations. |
| Rate of CR with partial hematologic recovery (CRh) after up to 6 cycles of therapy | after up to 6 cycles (each cycle is 28 days) | Rate of CR with partial hematologic recovery (CRh) after up to 6 cycles of therapy. Criteria for disease status / response assessment follow the ELN-2022 recommendations. |
| Time from initiation of treatment (C1D1) until achievement of CR or CRi | from start of treatment (C1D1) until up to 6 cycles (each cycle is 28 days) | Time from initiation of treatment (C1D1) until achievement of CR or CRi. Criteria for disease status / response assessment follow the ELN-2022 recommendations. |
| Objective response rate | at EOT, after up to 6 cycles therapy (each cycle is 28 days) | Objective response rate (CR, CRh, CRi, MLFS). Criteria for disease status / response assessment follow the ELN-2022 recommendations. |
| Event free survival (EFS) | From start of treatment to the date of relapse from CR or CRi, treatment failure (i.e., no CR or CRi after up to 6 cycles (each cycle is 28 days) of therapy or disease progression requiring treatment discontinuation), or death from any cause. | Event free survival (EFS), defined as the number of days from start of treatment to the date of relapse from CR or CRi, treatment failure (i.e., no CR or CRi after 6 cycles (each cycle is 28 days) of therapy or disease progression requiring treatment discontinuation), or death from any cause. |
| Overall survival (OS) | From start of treatment to date of death from any cause. OS will be assessed until 3 months after end of treatment of the last patient on study. | Overall survival (OS), defined as the number of days from start of treatment to death from any cause. After EOT, patients will be further followed up for survival until the end of the trial is reached (= last patient out, i.e. when the last surviving patient has reached the 3-month follow-up visit after EOT). Therefore, the duration of follow-up can differ between patients but is at least 3 months after EOT. |
| Descriptive assessment of measurable residual disease (MRD) levels on study treatment, determined by quantitative PCR or targeted next-generation sequencing | From Screening until EOT (after up to 6 cycles (each cycle is 28 days)) | Determined by quantitative PCR or targeted next-generation sequencing. Molecular profiling and MRD assessment of all patients will be carried out centrally (Hämatologisches Diagnostiklabor, Universitätsklinikum Leipzig), at least at screening, at the end of cycle 1, after cycle 4 and after cycle 6 resp. end of treatment (EOT). |
| Time to treatment discontinuation | From start of treatment to day of treatment discontinuation (within up to 6 cycles (each cycle is 28 days)) | Time to treatment discontinuation, defined as the number of days from start of treatment to premature stop of treatment. The stop date is the date the first cycle that was not given should have started as scheduled. This endpoint will be analyzed with death and progression or relapse as competing risk. |
| Rate of patients with at least one treatment interruption | From start of treatment until EOT (after up to 6 cycles (each cycle is 28 days)) | Rate of patients with at least one treatment interruption, i.e. a delay of the next cycle, and duration of treatment interruptions. |
| Delay of subsequent cycles, dose reductions or shortening/interruption of study drug administration | From start of treatment until EOT (after up to 6 cycles (each cycle is 28 days)) | Delay of subsequent cycles, dose reductions or shortening/interruption of study drug administration |
| Duration of patient hospitalization | From start of treatment until EOT (after up to 6 cycles (each cycle is 28 days)) | Duration of patient hospitalization, defined as days in hospital from start of treatment until EOT. |
| Quality of life (QoL) | From Screening until EOT (after up to 6 cycles (each cycle is 28 days)) | The established cancer-specific Core Quality of Life questionnaire QLQ-C30 from the EORTC (European Organisation for Research) will be used for QoL measurement, at screening and at the beginning of each cycle and at EOT. |
Countries
Germany
Contacts
PRINCIPAL_INVESTIGATORKlaus Metzeler, Prof. Dr.
Universitätsklinikum Leipzig, Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
Outcome results
None listed